RxDoctor Payments Data

Hannah Woodard

Nurse Practitioner · Augusta, GANPI 1063171247

Payments from drug & device makers

$4,439in general payments, 2019–2025

Across 196 payments — averaging $22.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$921
  • Novartis$558
  • Boston Scientific$511
  • Actelion Pharmaceuticals US, Inc.$321
  • E.r. Squibb & Sons, L.L.C.$295
  • Merck$288
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$4,425100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,439 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$55,297
Medicare patients
451
Services billed
563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban86$93,467
EntrestoSacubitril/Valsartan28$37,341
JardianceEmpagliflozin16$26,170
Repatha SureclickEvolocumab20$18,448
Praluent PenAlirocumab14$8,476
Metoprolol Succinate129$1,316
Losartan Potassium86$1,210
ClopidogrelClopidogrel Bisulfate73$961
Ranolazine ErRanolazine15$872
Rosuvastatin Calcium70$838
Carvedilol91$713
Atorvastatin Calcium98$699
Amlodipine Besylate124$678
Isosorbide Mononitrate ErIsosorbide Mononitrate54$621
Potassium Chloride22$561

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$259$93,46786 claims
NovartisEntresto$558$37,34128 claims
Boehringer IngelheimJardiance$247$26,17016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →